A randomized phase III study of docetaxel alone versus docetaxel plus S-1 in patients with previously treated non-small cell lung cancer: JMTO LC09-01.
Shinji AtagiTakashi DaimonKyoichi OkishioKiyoshi KomutaYoshio OkanoKoichi MinatoYoung Hak KimRyo UsuiChiharu TabataAtsuhisa TamuraMasaaki KawaharaPublished in: Thoracic cancer (2023)
The prematurely terminated study did not show the benefit of two cytotoxic agents over single-agent therapy for previously treated NSCLC patients.